← Grant listing · GrantsDue Pro

GREGoRi Innovation Projects (U01 Clinical Trial Optional)

National Institutes of Health · RFA-HG-27-013 · Deadline: October 30, 2026 · Advertised ceiling: $500k

Program-level history — this opportunity doesn't publish per-opportunity awards, so these numbers describe its parent program (CFDA 93.172, Human Genome Research), not this competition alone. Labeled that way on purpose.

Draw-down reality (program)

Across 185 completed awards in this program (FY2021+ sample, USAspending outlay records), grantees ultimately drew a median 96% of obligated funds. A median well under 100% means underspend or early closure is common here — worth knowing before promising a spend-down timeline.

Listing summary

The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying rare genetic disorders. This Notice of Funding Opportunity is intended to stimulate the development and testing of highly innovative experimental or computational approaches for rare disease diagnosis, that have the potential to make transformative improvements to the current state of the art.

Eligibility: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations (other), Nonprofits with 501(c)(3), other than higher education, Nonprofits without 501(c)(3), Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others · Categories: Health · official listing ↗

Sources: NIH RePORTER (opportunity-exact) and USAspending (program-level), labeled per section. GrantsDue computes summaries only; verify anything critical against the originals. Methodology.